Literature DB >> 17050816

Bacterial identification, clinical significance, and antimicrobial susceptibilities of Acinetobacter ursingii and Acinetobacter schindleri, two frequently misidentified opportunistic pathogens.

Laurent Dortet1, Patrick Legrand, Claude-James Soussy, Vincent Cattoir.   

Abstract

The species belonging to the Acinetobacter genus are currently reported as opportunistic pathogens in hospitalized patients with underlying predispositions. However, except for the Acinetobacter calcoaceticus-Acinetobacter baumannii complex, the identification of other species is frequently unreliable, especially for Acinetobacter ursingii and Acinetobacter schindleri, newly described in 2001. Thus, the clinical significance, phenotypic features, and antimicrobial susceptibilities of these two misidentified species remain unclear. Of 456 Acinetobacter sp. clinical strains isolated from 2002 to 2005 in Henri Mondor Hospital, 15 isolates (10 A. ursingii and 5 A. schindleri isolates) were studied. They were characterized using a phenotypic approach (API 20 NE and VITEK 2 systems), 16S rRNA gene sequencing, and susceptibility to antimicrobial agents with evaluation of impact in clinical relevance. The two corresponding type strains were also included for comparison. All isolates were identified to the species level using molecular tools, whereas the phenotypic methods remained unreliable due to the absence of these two species in the manufacturers' databases. However, the API 20 NE system appeared to be a reasonably reliable phenotypic alternative for the identification of A. ursingii when the numerical code 0000071 was found. Conversely, no discriminative phenotypic alternative existed for A. schindleri isolates. Concerning antimicrobial susceptibility, A. ursingii strains appeared to be more resistant to antibiotics than A. schindleri strains, which could imply therapeutic consequences. Finally, the prevalence of infections caused by A. ursingii and A. schindleri (representing 9.7% and 4.8% of non-A. calcoaceticus-A. baumannii complex strains, respectively) seems to be underestimated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17050816      PMCID: PMC1698419          DOI: 10.1128/JCM.01535-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  28 in total

1.  Aerators as a reservoir of Acinetobacter junii: an outbreak of bacteraemia in paediatric oncology patients.

Authors:  I Kappstein; H Grundmann; T Hauer; C Niemeyer
Journal:  J Hosp Infect       Date:  2000-01       Impact factor: 3.926

2.  Naturally transformable Acinetobacter sp. strain ADP1 belongs to the newly described species Acinetobacter baylyi.

Authors:  Mario Vaneechoutte; David M Young; L Nicholas Ornston; Thierry De Baere; Alexandr Nemec; Tanny Van Der Reijden; Emma Carr; Ingela Tjernberg; Lenie Dijkshoorn
Journal:  Appl Environ Microbiol       Date:  2006-01       Impact factor: 4.792

3.  16S rRNA gene sequencing versus the API 20 NE system and the VITEK 2 ID-GNB card for identification of nonfermenting Gram-negative bacteria in the clinical laboratory.

Authors:  P P Bosshard; R Zbinden; S Abels; B Böddinghaus; M Altwegg; E C Böttger
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

Review 4.  Clinical impact and pathogenicity of Acinetobacter.

Authors:  M-L Joly-Guillou
Journal:  Clin Microbiol Infect       Date:  2005-11       Impact factor: 8.067

5.  Acinetobacter ursingii sp. nov. and Acinetobacter schindleri sp. nov., isolated from human clinical specimens.

Authors:  A Nemec; T De Baere; I Tjernberg; M Vaneechoutte; T J van der Reijden; L Dijkshoorn
Journal:  Int J Syst Evol Microbiol       Date:  2001-09       Impact factor: 2.747

6.  Nosocomial bacteremia due to an as yet unclassified acinetobacter genomic species 17-like strain.

Authors:  Jesús Rodriguez-Baño; Sara Martí; Anna Ribera; Felipe Fernández-Cuenca; Lenie Dijkshoorn; Alexandr Nemec; Miquel Pujol; Jordi Vila
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

7.  Recognition of two novel phenons of the genus Acinetobacter among non-glucose-acidifying isolates from human specimens.

Authors:  A Nemec; L Dijkshoorn; P Jezek
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

8.  Clinical and microbiological characteristics of bacteremia caused by Acinetobacter lwoffii.

Authors:  S C Ku; P R Hsueh; P C Yang; K T Luh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-07       Impact factor: 3.267

9.  Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility.

Authors:  H Wisplinghoff; M B Edmond; M A Pfaller; R N Jones; R P Wenzel; H Seifert
Journal:  Clin Infect Dis       Date:  2000-10-04       Impact factor: 9.079

10.  Septicemia due to Acinetobacter junii.

Authors:  Hans-Jörg Linde; Joachim Hahn; Ernst Holler; Udo Reischl; Norbert Lehn
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

View more
  45 in total

1.  Rothia aeria acute bronchitis: the first reported case.

Authors:  J Michon; D Jeulin; J-M Lang; V Cattoir
Journal:  Infection       Date:  2010-04-01       Impact factor: 3.553

Review 2.  The Lung Microbiome and Its Role in Pneumonia.

Authors:  Benjamin G Wu; Leopoldo N Segal
Journal:  Clin Chest Med       Date:  2018-12       Impact factor: 2.878

3.  In vivo selection of reduced susceptibility to carbapenems in Acinetobacter baumannii related to ISAba1-mediated overexpression of the natural bla(OXA-66) oxacillinase gene.

Authors:  Samy Figueiredo; Laurent Poirel; Jacques Croize; Christine Recule; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2009-03-23       Impact factor: 5.191

4.  Multi-center evaluation of the VITEK® MS system for mass spectrometric identification of non-Enterobacteriaceae Gram-negative bacilli.

Authors:  R Manji; M Bythrow; J A Branda; C-A D Burnham; M J Ferraro; O B Garner; R Jennemann; M A Lewinski; A B Mochon; G W Procop; S S Richter; J A Rychert; L Sercia; L F Westblade; C C Ginocchio
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-09-10       Impact factor: 3.267

5.  Identification, genotypic relation, and clinical features of colistin-resistant isolates of Acinetobacter genomic species 13BJ/14TU from bloodstreams of patients in a university hospital.

Authors:  Seung Yeob Lee; Jong Hee Shin; Kyung Hwa Park; Ju Hee Kim; Myung Geun Shin; Soon Pal Suh; Dong Wook Ryang; Soo Hyun Kim
Journal:  J Clin Microbiol       Date:  2014-01-08       Impact factor: 5.948

Review 6.  Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.

Authors:  Darren Wong; Travis B Nielsen; Robert A Bonomo; Paul Pantapalangkoor; Brian Luna; Brad Spellberg
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

7.  Detection of New Delhi metallo-β-lactamase (encoded by blaNDM-1) in Acinetobacter schindleri during routine surveillance.

Authors:  Patrick McGann; Michael Milillo; Robert J Clifford; Erik Snesrud; Lindsay Stevenson; Michael G Backlund; Helen B Viscount; Reyes Quintero; Yoon I Kwak; Michael J Zapor; Paige E Waterman; Emil P Lesho
Journal:  J Clin Microbiol       Date:  2013-04-03       Impact factor: 5.948

8.  Bacteremia due to Acinetobacter genomic species 10.

Authors:  Shu-Chen Kuo; Chang-Phone Fung; Yi-Tzu Lee; Chien-Pei Chen; Te-Li Chen
Journal:  J Clin Microbiol       Date:  2009-12-02       Impact factor: 5.948

9.  Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.

Authors:  Laurent Poirel; Wejdene Mansour; Olfa Bouallegue; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2008-02-25       Impact factor: 5.191

10.  Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii.

Authors:  Pauline D Mugnier; Laurent Poirel; Thierry Naas; Patrice Nordmann
Journal:  Emerg Infect Dis       Date:  2010-01       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.